Summary: The Centers for Medicare & Medicaid Services modified its Pre-Exposure Prophylaxis (PrEP) for HIV Prevention coverage policy, with an effective date of April 8, 2026. Here's what billing teams need to know before claims start moving through.
CMS updated its PrEP HIV prevention coverage policy as part of ongoing efforts to align with current U.S. Preventive Services Task Force (USPSTF) guidance. This change affects how Medicare covers PrEP-related services — including the medications, lab work, and clinical visits tied to PrEP management. The policy does not list specific CPT or HCPCS codes in the available documentation, but PrEP billing touches multiple code families across preventive services, office visits, and drug coverage. If your practice or pharmacy bills Medicare for PrEP-related services, this modification demands your attention now, not after April 8.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Pre-Exposure Prophylaxis (PrEP) for HIV Prevention |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | April 8, 2026 |
| Impact Level | High |
| Specialties Affected | Infectious disease, primary care, internal medicine, pharmacy, preventive services, sexual health clinics |
| Key Action | Audit your PrEP billing workflows and preventive service claim submissions against the updated coverage policy before April 8, 2026 |
CMS PrEP HIV Prevention Coverage Criteria and Medical Necessity Requirements 2026
The real question most billing teams are asking right now: what does CMS actually cover under this updated PrEP HIV prevention coverage policy, and what does medical necessity look like for Medicare beneficiaries?
PrEP — primarily delivered as oral tenofovir-based regimens or, more recently, as long-acting injectable cabotegravir — is indicated for HIV-negative individuals at high risk of HIV acquisition. CMS coverage aligns with USPSTF Grade A recommendation status, which under the Affordable Care Act triggers zero cost-sharing requirements for preventive services in most plan types. The modification to this policy likely tightens or clarifies how that coverage applies across Medicare's various parts.
Under Medicare, PrEP services span multiple coverage buckets. The medication itself typically falls under Medicare Part D. The clinical visits and lab monitoring tied to PrEP — HIV testing, renal function panels, STI screening — can qualify as preventive services under Part B. Medical necessity for the monitoring visits and labs depends on documented patient risk factors and adherence to prescribing guidelines, including the CDC's PrEP clinical practice guidelines.
Prior authorization requirements vary by Part D plan. Many Medicare Part D sponsors do require prior authorization for PrEP medications before reimbursement. Your billing team should confirm the specific prior auth requirements for each Part D plan your patients use — this is where denials pile up fast.
The updated coverage policy may also clarify how Medicare handles the long-acting injectable form of PrEP (cabotegravir, marketed as Apretude). Injectable PrEP has a different billing pathway than oral medications and may involve both a medical benefit (Part B) for administration and a pharmacy benefit (Part D) for the drug itself. If your practice administers injectable PrEP, this distinction matters enormously for reimbursement.
Coverage Indications at a Glance
Because the published policy document does not include a detailed indication-by-indication breakdown with specific codes, this table reflects the standard Medicare PrEP coverage framework consistent with USPSTF and CMS guidance. Confirm each row against the full policy text at the effective date.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| HIV-negative adults at high risk of HIV acquisition — oral PrEP (tenofovir-based) | Covered | Part D drug codes; preventive visit codes | Zero cost-sharing under ACA preventive mandate for qualifying plans |
| HIV-negative adults at high risk — long-acting injectable PrEP (cabotegravir) | Covered (confirm under updated policy) | Part B administration + Part D drug | Dual-benefit billing; prior auth likely required |
| Associated HIV testing (before and during PrEP) | Covered | Confirm specific lab codes against policy | Required at initiation and on schedule per CDC guidelines |
| STI screening and renal function monitoring visits | Covered as preventive services | Office visit and lab codes | Medical necessity documentation required |
| PrEP for individuals with unknown HIV status | Not Covered / Requires Clarification | N/A | HIV-negative status must be confirmed before PrEP initiation |
Note: This table is derived from the general CMS and USPSTF framework. The specific policy document does not list codes or indication-level criteria. Verify all rows against the full policy text before April 8, 2026.
CMS PrEP HIV Prevention Billing Guidelines and Action Items 2026
This is where billing teams need to focus their energy in the weeks before April 8.
| # | Action Item |
|---|---|
| 1 | Pull the full policy text before April 8, 2026. The available documentation for this modification does not include detailed code-level criteria. Access the complete policy at the source before the effective date. Don't build workflows off incomplete information. |
| 2 | Separate your Part B and Part D billing workflows for PrEP. Oral PrEP medications run through Part D. Injectable PrEP administration may qualify for Part B reimbursement. If your team is billing both under the same workflow, you're creating claim denial risk. |
| 3 | Confirm prior authorization requirements for each patient's Part D plan. Prior auth for PrEP medications is common across Medicare Part D sponsors. Document the PA status before dispensing or administering. A denied claim for a $3,000+ injectable regimen is not a small problem. |
| 4 | Review how you document medical necessity for PrEP monitoring visits. Lab monitoring (HIV status, renal function, STI screening) tied to PrEP management must show a clear clinical basis. Your documentation should reflect the CDC prescribing guidelines. Vague notes won't hold up on audit. |
| 5 | Check whether your preventive service claims reflect the zero cost-sharing requirement. Under the ACA, USPSTF Grade A recommendations trigger no cost-sharing for beneficiaries in qualifying plans. If your team is applying copays or coinsurance to covered PrEP services, you're creating compliance exposure — not just a billing error. |
| 6 | Flag injectable PrEP patients for a billing pathway review. Long-acting injectable cabotegravir sits at the intersection of Part B and Part D in a way that creates real complexity. If you administer Apretude in-office, confirm your administration coding, drug billing pathway, and any MAC-level guidance before April 8. |
| 7 | Talk to your compliance officer if any of this is unclear. PrEP billing sits at the intersection of preventive services, drug coverage, and sexual health — three areas where Medicare billing rules get complicated fast. If you're not certain how the updated coverage policy applies to your patient population, loop in your compliance officer before the effective date. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for PrEP HIV Prevention Under This Policy
The policy document for this CMS modification does not list specific CPT, HCPCS, or ICD-10 codes. Do not rely on invented codes for claims submission.
That said, PrEP billing in Medicare involves several well-established code families. Your billing team should confirm each against the full policy text and current CMS billing guidelines:
Commonly Used Code Categories for PrEP Services (Verify Against Full Policy)
| Code Type | Service Area | Notes |
|---|---|---|
| Part D NDC codes | Oral PrEP (tenofovir alafenamide / emtricitabine; tenofovir disoproxil fumarate / emtricitabine) | Billed through pharmacy benefit; prior auth commonly required |
| Part D NDC codes | Long-acting injectable cabotegravir (Apretude) | Drug component billed through Part D |
| Part B HCPCS (J-code) | Injectable cabotegravir administration | Medical benefit for in-office administration; verify current J-code assignment |
| Preventive visit CPT codes | PrEP-related office visits qualifying as preventive | Confirm eligibility for zero cost-sharing |
| Laboratory CPT codes | HIV testing, STI panels, renal function | Required at initiation and per monitoring schedule |
| ICD-10-CM | HIV-negative status, high-risk sexual behavior, PrEP status | Documentation codes to support medical necessity |
Do not use this table as a substitute for the full policy code list. CMS did not publish specific codes in the available documentation for this modification. Confirm all codes against the complete policy text and your MAC's local coverage determination guidance.
How MACs May Apply This Policy Differently
This is worth a separate mention. Medicare Administrative Contractors can issue local coverage determinations that add requirements on top of national policy. If your patients are concentrated in a specific MAC jurisdiction, check whether that MAC has issued any LCD guidance on PrEP services.
Some MACs have historically been more restrictive about what counts as an "at-risk" qualifying indication for PrEP coverage. What passes as sufficient medical necessity documentation in one jurisdiction may not fly in another. Know your MAC's position before April 8.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.